B2BROKER
8.2.2024 09:28:35 CET | Business Wire | Press release
B2Broker, a global powerhouse of liquidity and technology in the B2B sector for crypto, Forex and financial sectors, has partnered with Tools for Brokers (TFB), which provides elite solutions to brokers, liquidity providers, prop trading agencies and hedge funds.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240208106794/en/
B2Broker partners with Tools for Brokers to integrate Trade Processor liquidity bridge into its existing ecosystem, enhancing the flexibility and efficiency of liquidity services it provides. (Graphic: Business Wire)
B2Broker aims to integrate TFB’s Trade Processor liquidity bridge into its existing ecosystem, enhancing the flexibility and efficiency of liquidity services it provides.
Importance of B2Broker and TFB Partnership
This collaboration combines B2Broker’s robust liquidity services with TFB’s cutting-edge Trade Processor technology. Here’s what you can expect from the partnership:
Enhanced Risk Mitigation - Trade Processor liquidity gateway introduces the trade routing feature that significantly elevates risk management capabilities for B2Broker clients. The platform can also provide advanced trade routing solutions to retail brokers with their MT4/MT5 servers. Traders can also seamlessly switch between A-Book and B-Book, increasing their flexibility and ability to adapt to market trends.
Elevated Access - With this integration, B2Broker clients will seamlessly access MT4, MT5 and cTrader platforms. The external FIX API integration is also possible for connecting third-party platforms.
Intuitive UI and Advanced Analytics - the Trade Processor also streamlines the digital user interface, making it easy to obtain essential data and access B2Broker’s features. The trading History page now overviews closed positions and all relevant details. Additional pages allow clients to analyse open position stats and exposure metrics and monitor the server performance.
Arthur Azizov, CEO of B2Broker, shared his thoughts on the partnership: "Our collaboration with Tools for Brokers directly supports our goal to deliver innovative technology to clients. TFB's Trade Processor upgrades our offerings with improved risk management and seamless integration across major trading platforms. At the same time, this partnership opens up B2Broker's extensive liquidity pool of over 800 pairs across eight asset classes to TFB users. It’s a mutual exchange of strengths that promises to enhance the value we, B2Broker and TFB, aim to deliver to our clients."
Alexey Kutsenko, the CEO at Tools for Brokers, outlined his excitement for the upcoming collaboration: “We are excited to partner with B2Broker. The company is well-known for its powerful ecosystem of products for brokers. I am confident that together we will create an even stronger solution for B2Brokers’ clients and help them grow faster and stay resilient.”
About Tools for Brokers
Tools for Brokers (TFB) is a global tech provider that serves retail brokers, LPs, prop trading firms and hedge funds operating on multiple platforms like MT4, MT5, Match-Trader and cTrader. TFB’s solutions are powered by their cutting-edge Trade Processor liquidity bridge. The core technology is further elevated by data analytics, risk mitigation tools, money management solutions and a single digital hub to manage TFB plugins effortlessly.
For more information, visit www.t4b.com
B2Broker’s Services
B2Broker is a global leader in the liquidity and fintech sector. B2Broker provides B2B services to forex brokers, crypto exchange platforms, prop traders, crypto spot brokers, multi-asset brokers and many other industries. B2Broker offers over 800 liquidity instruments supported by eight different asset classes. Moreover, the platform features payment processing solutions, white-label solutions, back-office, and numerous other mechanisms to create a full-stop liquidity and business management service for their B2B clients.
For more information, visit b2broker.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240208106794/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom